Breaking Barriers in Immuno-Oncology: Mechanistic Insights into Immune Checkpoint Inhibitor Resistance and Implications for Health Economics and Outcomes Research and Value Assessment

Immune checkpoint inhibitors deliver transformative outcomes, yet real‑world durability is often limited by primary and acquired resistance. This article explores the biological foundations of ICI resistance and outlines how integrating these insights into HEOR models can improve value assessment and real‑world decision‑making.
The Essential Role of Real World Evidence Combating COVID-19

Are you prepared for potential accelerated approval requirements?
ISPE’s Position on Real World Evidence (RWE)

Read more about the February 2020 position on RWE from ISPE.
Lack of Label Alignment & Patient Safety Implications

Read the full article from UBC’s pharmacovigilance team in Drugs Real World Outcomes.
Risk Management Plan Development & Implementation

Listen to the full podcast from UBC with PharmaVOICE here.
Top Trends in Oncology Patient Support

Find out what access and adherence challenges patients will need to overcome in the evolving oncology market.
Are You Ready For Sentinel? | New RWE Safety Initiative

With continued investment in the RWE space, find out how to meet the needs of regulators, payers, and prescribers.
Immunogenicity: Meeting the Safety Reporting Requirements

Discover why it is imperative to assess the potential of therapeutic proteins throughout the product lifecycle.
DIA 2019: Watch the Wrap-up of UBC’s Participation

See more of the developments UBC’s evidence development and safety & risk management teams discussed.